Indoco Remedies Submits Compliance Certificate under SEBI (Depositories and Participants) Regulations, 2018
Indoco Remedies submitted its compliance certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2025, confirming dematerialization process compliance.
This is a standard and mandatory regulatory filing that does not typically have a significant impact on the company's stock price or business operations.
The announcement is a routine regulatory compliance filing, indicating standard operational adherence without any specific positive or negative financial or operational news.
Indoco Remedies Limited has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2025. The certificate, issued by MUFG Intime India Private Limited, the company's Registrar and Transfer Agent, confirms that: * Securities received for dematerialization during the quarter were confirmed (accepted/rejected) to the depositories. * Securities comprised in the said certificates have been listed on the stock exchanges where earlier issued securities are listed. * Security certificates received for dematerialization were confirmed/rejected, mutilated, and cancelled after due verification, and the name of the depositories was substituted in the register of members within prescribed timelines. * No requests for rematerialization were received.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.